{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:59:51Z","timestamp":1771469991749,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>This study was motivated by the increasing global incidence of benign prostatic hyperplasia (BPH) and the promising potential of nutraceuticals as complementary therapies in ameliorating its burden. We report the safety profile of<jats:italic>C. esculenta<\/jats:italic>tuber extracts, a novel nutraceutical in benign prostate hyperplasia in a rat model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, forty-five male albino rats were randomly assigned to 9 groups of 5 rats each. Group 1 (normal control) received olive oil and normal saline. Group 2 (BPH untreated group) received 3\u00a0mg\/kg of testosterone propionate (TP) and normal saline, and group 3 (positive control) received 3\u00a0mg\/kg of TP and 5\u00a0mg\/kg of finasteride. Treatment groups 4, 5, 6, 7, 8, and 9 received 3\u00a0mg\/kg of TP and a middle dose (200\u00a0mg\/kg) of LD50 of ethanol crude tuber extract of<jats:italic>C. esculenta<\/jats:italic>(ECTECE) or hexane, dichloromethane, butanone, ethyl acetate and aqueous fractions of ECTECE respectively for a period of 28 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The negative controls showed a significant (p\u2009&lt;\u20090.05) increase in mean relative prostate weight (approximately 5 times) as well as a reduction in relative testes weight (approximately 1.4 times less). There was no significant (p\u2009&gt;\u20090.05) difference in the mean relative weights of most vital organs: liver, kidneys, and heart. This was also observed in hematological parameters: RBC, hemoglobin, HCT, MCV, MCH, MCHC, and platelets counts. In general, we note that the effects of the well-established drug finasteride on the biochemical parameters and histology of selected organs are comparable to those of<jats:italic>C. esculenta<\/jats:italic>fractions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrates that C. esculenta tuber extracts provide potentially safe nutraceutical if applied in the management of benign prostate hyperplasia based on a rat model.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12906-023-04018-4","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T03:26:31Z","timestamp":1686194791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety profile of colocasia esculenta tuber extracts in benign prostate hyperplasia"],"prefix":"10.1186","volume":"23","author":[{"given":"Deusdedit","family":"Tusubira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"Aja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonasi","family":"Munezero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Ssedyabane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathim","family":"Namale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josiah E.","family":"Ifie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Agu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement O.","family":"Ajayi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joash","family":"Okoboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"issue":"10159","key":"4018_CR1","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/S0140-6736(18)31891-9","volume":"392","author":"regional Global","year":"2018","unstructured":"Global regional. National age-sex-specific mortality and life expectancy, 1950\u20132017: a systematic analysis for the global burden of Disease Study 2017. Lancet (London England). 2018;392(10159):1684\u2013735.","journal-title":"Lancet (London England)"},{"issue":"1","key":"4018_CR2","first-page":"1","volume":"2","author":"B Chughtai","year":"2016","unstructured":"Chughtai B, Forde JC, Thomas DDM, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA. Benign prostatic hyperplasia. Nat reviews Disease primers. 2016;2(1):1\u201315.","journal-title":"Nat reviews Disease primers"},{"issue":"9","key":"4018_CR3","doi-asserted-by":"publisher","first-page":"734e731","DOI":"10.1016\/j.urolonc.2020.05.015","volume":"38","author":"EM Sohlberg","year":"2020","unstructured":"Sohlberg EM, Thomas IC, Yang J, Kapphahn K, Daskivich TJ, Skolarus TA, Shelton JB, Makarov DV, Bergman J, Bang CK, et al. Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration. Urol Oncol. 2020;38(9):734e731\u2013734e710.","journal-title":"Urol Oncol"},{"key":"4018_CR4","doi-asserted-by":"crossref","unstructured":"Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. 2021, 127(6):722\u20138.","DOI":"10.1111\/bju.15286"},{"issue":"7320","key":"4018_CR5","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/bmj.323.7320.1042","volume":"323","author":"MJ Barry","year":"2001","unstructured":"Barry MJ, Roehrborn CG. Benign prostatic hyperplasia. BMJ. 2001;323(7320):1042\u20136.","journal-title":"BMJ"},{"key":"4018_CR6","first-page":"1","volume":"22","author":"TA Gossel","year":"2004","unstructured":"Gossel TA, Wuest JR. New drugs of 2004 for treatment of benign prostatic hyperplasia: Avodart and Uroxatal. Contin Educ Pharm. 2004;22:1\u20134.","journal-title":"Contin Educ Pharm"},{"key":"4018_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpsychires.2019.08.002","volume":"126","author":"Q Liu","year":"2020","unstructured":"Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study. J Psychiatr Res. 2020;126:134\u201340.","journal-title":"J Psychiatr Res"},{"issue":"5","key":"4018_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.21037\/tau.2019.10.01","volume":"8","author":"SD Lokeshwar","year":"2019","unstructured":"Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE Jr, Terris MK, Klaassen Z. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Translational Androl Urol. 2019;8(5):529.","journal-title":"Translational Androl Urol"},{"issue":"2","key":"4018_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/pcan.2011.43","volume":"15","author":"AP Chokkalingam","year":"2012","unstructured":"Chokkalingam AP, Yeboah ED, Demarzo A, Netto G, Yu K, Biritwum RB, Tettey Y, Adjei A, Jadallah S, Li Y, et al. Prevalence of BPH and lower urinary tract symptoms in West Africans. Prostate Cancer Prostatic Dis. 2012;15(2):170\u20136.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"4018_CR10","first-page":"1","volume":"6","author":"ED Yeboah","year":"2016","unstructured":"Yeboah ED, PREVALENCE OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER IN AFRICANS AND AFRICANS IN THE DIASPORA. J West Afr Coll Surg. 2016;6(4):1\u201330.","journal-title":"J West Afr Coll Surg"},{"key":"4018_CR11","doi-asserted-by":"crossref","unstructured":"Peter N, Michael C. Benign Prostatic Hyperplasia (BPH) in an elderly ugandan male. MMJ 2014, 46(1).","DOI":"10.1002\/9781118437889.ch16"},{"issue":"8","key":"4018_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s12325-010-0041-6","volume":"27","author":"P Pais","year":"2010","unstructured":"Pais P. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5\u03b1-reductase II. Adv therapy. 2010;27(8):555\u201363.","journal-title":"Adv therapy"},{"issue":"1","key":"4018_CR13","first-page":"87","volume":"95","author":"CG Roehrborn","year":"2011","unstructured":"Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin. 2011;95(1):87\u2013100.","journal-title":"Med Clin"},{"issue":"11","key":"4018_CR14","first-page":"E447","volume":"12","author":"F Bajunirwe","year":"2018","unstructured":"Bajunirwe F, Stothers L, Berkowitz J, Macnab AJ. Prevalence estimates for lower urinary tract symptom severity among men in Uganda and sub-saharan Africa based on regional prevalence data. Can Urol Association journal = Journal de l\u2019Association des urologues du Can. 2018;12(11):E447\u2013e452.","journal-title":"Can Urol Association journal = Journal de l\u2019Association des urologues du Can"},{"issue":"10","key":"4018_CR15","first-page":"915","volume":"35","author":"G Corona","year":"2012","unstructured":"Corona G, Rastrelli G, Maseroli E, Balercia G, Sforza A, Forti G, Mannucci E, Maggi M. Inhibitors of 5\u03b1-reductase-related side effects in patients seeking medical care for sexual dysfunction. J Endocrinol Investig. 2012;35(10):915\u201320.","journal-title":"J Endocrinol Investig"},{"issue":"2","key":"4018_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1750-9378-6-S2-S5","volume":"6","author":"OJ Ogunbiyi","year":"2011","unstructured":"Ogunbiyi OJ. Impact of health system challenges on prostate cancer control: health care experiences in Nigeria. Infect Agents Cancer. 2011;6(2):5.","journal-title":"Infect Agents Cancer"},{"key":"4018_CR17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fphar.2020.00658","volume":"11","author":"Z-J Yu","year":"2020","unstructured":"Yu Z-J, Yan H-L, Xu F-H, Chao H-C, Deng L-H, Xu X-D, Huang J-B, Zeng T. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Front Pharmacol. 2020;11:658.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4018_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1742-1241.2007.01635.x","volume":"62","author":"M Emberton","year":"2008","unstructured":"Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the prostate research on Behaviour and Education (PROBE) Survey. Int J Clin Pract. 2008;62(1):18\u201326.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"4018_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00345-019-02933-1","volume":"38","author":"S \u00dcckert","year":"2020","unstructured":"\u00dcckert S, Kedia GT, Tsikas D, Simon A, Bannowsky A, Kuczyk MA. Emerging drugs to target lower urinary tract symptomatology (LUTS)\/benign prostatic hyperplasia (BPH): focus on the prostate. World J Urol. 2020;38(6):1423\u201335.","journal-title":"World J Urol"},{"key":"4018_CR20","doi-asserted-by":"crossref","unstructured":"Dunn MW, Kazer MW. Prostate cancer overview. In: Seminars in oncology nursing: 2011: Elsevier; 2011: 241\u201350.","DOI":"10.1016\/j.soncn.2011.07.002"},{"issue":"1","key":"4018_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/MOU.0000000000000007","volume":"24","author":"J Silva","year":"2014","unstructured":"Silva J, Silva CM, Cruz F. Current medical treatment of lower urinary tract symptoms\/BPH: do we have a standard? Curr Opin Urol. 2014;24(1):21\u20138.","journal-title":"Curr Opin Urol"},{"issue":"Suppl 1","key":"4018_CR22","first-page":"7","volume":"22","author":"B Van Asseldonk","year":"2015","unstructured":"Van Asseldonk B, Barkin J, Elterman DS. Medical therapy for benign prostatic hyperplasia: a review. Can J Urol. 2015;22(Suppl 1):7\u201317.","journal-title":"Can J Urol"},{"issue":"1","key":"4018_CR23","first-page":"33","volume":"32","author":"SA Saka","year":"2021","unstructured":"Saka SA, Yusuf AA, Campus S. Drug therapy problem in elderly outpatients with benign prostatic hyperplasia. West Afr J Pharm. 2021;32(1):33\u201344.","journal-title":"West Afr J Pharm"},{"key":"4018_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fphar.2017.00234","volume":"8","author":"C Eleazu","year":"2017","unstructured":"Eleazu C, Eleazu K, Kalu W. Management of benign prostatic hyperplasia: could dietary polyphenols be an alternative to existing therapies? Front Pharmacol. 2017;8:234.","journal-title":"Front Pharmacol"},{"key":"4018_CR25","doi-asserted-by":"crossref","unstructured":"Cicero AFG, Allkanjari O, Busetto GM, Cai T, Largan\u00e0 G, Magri V, Perletti G, Robustelli Della Cuna FS, Russo GI, Stamatiou K et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Archivio italiano di urologia andrologia: organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2019, 91(3).","DOI":"10.4081\/aiua.2019.3.139"},{"issue":"3","key":"4018_CR26","first-page":"192","volume":"10","author":"J Curtis Nickel","year":"2008","unstructured":"Curtis Nickel J, Shoskes D, Roehrborn CG, Moyad M. Nutraceuticals in prostate disease: the urologist\u2019s role. Rev Urol. 2008;10(3):192\u2013206.","journal-title":"Rev Urol"},{"key":"4018_CR27","unstructured":"Talwana H, Serem A, Ndabikunze B, Nandi J, Tumuhimbise R, Kaweesi T, Chumo C, Palapala VA. Production Status and Prospects of Cocoyam (Colocasia esculenta L. Schott.) in East Africa. 2009."},{"issue":"8","key":"4018_CR28","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.3390\/su13084483","volume":"13","author":"OA Otekunrin","year":"2021","unstructured":"Otekunrin OA, Sawicka B, Adeyonu AG, Otekunrin OA, Racho\u0144 L. Cocoyam [Colocasia esculenta (L.) Schott]: exploring the production, Health and Trade Potentials in Sub-Saharan Africa. Sustainability. 2021;13(8):4483.","journal-title":"Sustainability"},{"issue":"2","key":"4018_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4103\/2231-0738.84188","volume":"1","author":"R Prajapati","year":"2011","unstructured":"Prajapati R, Kalariya M, Umbarkar R, Parmar S, Sheth N. Colocasia esculenta: a potent indigenous plant. Int J Nutr Pharmacol Neurol Dis. 2011;1(2):90.","journal-title":"Int J Nutr Pharmacol Neurol Dis"},{"issue":"2","key":"4018_CR30","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/molecules26020450","volume":"26","author":"K Mitsunari","year":"2021","unstructured":"Mitsunari K, Miyata Y, Matsuo T, Mukae Y, Otsubo A, Harada J, Kondo T, Matsuda T, Ohba K, Sakai H. Pharmacological Effects and potential clinical usefulness of polyphenols in Benign Prostatic Hyperplasia. Molecules. 2021;26(2):450.","journal-title":"Molecules"},{"issue":"6","key":"4018_CR31","first-page":"1945","volume":"8","author":"S Keerthy","year":"2019","unstructured":"Keerthy S, Joshi KH. The pharmacological importance of Colocasia esculenta Linn: a review. J Pharmacognosy Phytochemistry. 2019;8(6):1945\u20138.","journal-title":"J Pharmacognosy Phytochemistry"},{"issue":"9","key":"4018_CR32","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/ptr.1712","volume":"19","author":"AC Brown","year":"2005","unstructured":"Brown AC, Reitzenstein JE, Liu J, Jadus MR. The anti-cancer effects of poi (Colocasia esculenta) on colonic adenocarcinoma cells in vitro. Phytother Res. 2005;19(9):767\u201371.","journal-title":"Phytother Res"},{"issue":"8","key":"4018_CR33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3109\/13880209.2015.1014923","volume":"53","author":"M Kalariya","year":"2015","unstructured":"Kalariya M, Prajapati R, Parmar SK, Sheth N. Effect of hydroalcoholic extract of leaves of Colocasia esculenta on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Pharm Biol. 2015;53(8):1239\u201342.","journal-title":"Pharm Biol"},{"issue":"3","key":"4018_CR34","first-page":"129","volume":"5","author":"MH Islam","year":"2018","unstructured":"Islam MH, Mostafa MN, Rahmatullah M. Antihyperglycemic activity of methanolic extracts of corms of Colocasia esculenta var esculenta. Eur J Pharm Med Res. 2018;5(3):129\u201332.","journal-title":"Eur J Pharm Med Res"},{"issue":"2","key":"4018_CR35","first-page":"1","volume":"14","author":"AK Tripathi","year":"2013","unstructured":"Tripathi AK, Kohli S. Phytochemical screening and evaluation of antidiabetic activity of Colocasia esculenta (L) leaves on STZ induced diabetic rats. Adv Pharmacol Toxicol. 2013;14(2):1.","journal-title":"Adv Pharmacol Toxicol"},{"key":"4018_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S2222-1808(14)60711-8","volume":"4","author":"CO Eleazu","year":"2014","unstructured":"Eleazu CO, Okafor PN, Ifeoma I. Biochemical basis of the use of cocoyam (Colocassia esculenta L.) in the dietary management of diabetes and its complications in streptozotocin induced diabetes in rats. Asian Pac J Trop Disease. 2014;4:705\u2013S711.","journal-title":"Asian Pac J Trop Disease"},{"issue":"4","key":"4018_CR37","first-page":"314","volume":"7","author":"S Shithi","year":"2013","unstructured":"Shithi S, Mohammed R. Antihyperglycemic and antinociceptive activities of methanolic extract of Colocasia esculenta (L.) Schott stems: a preliminary study. American-Eurasian J Sustainable Agric. 2013;7(4):314\u20139.","journal-title":"American-Eurasian J Sustainable Agric"},{"issue":"12","key":"4018_CR38","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1080\/13880209.2016.1190383","volume":"54","author":"C Eleazu","year":"2016","unstructured":"Eleazu C. Characterization of the natural products in cocoyam (Colocasia esculenta) using GC\u2013MS. Pharm Biol. 2016;54(12):2880\u20135.","journal-title":"Pharm Biol"},{"key":"4018_CR39","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.biopha.2017.12.061","volume":"99","author":"DC Nyonseu Nzebang","year":"2018","unstructured":"Nyonseu Nzebang DC, Ngaha Njila MI, Bend EF, Oundoum Oundoum PC, Koloko BL, Bogning Zangueu C, Belle Ekedi P, Sameza M, Massoma Lemb\u00e8 D. Evaluation of the toxicity of Colocasia esculenta (Aracaceae): preliminary study of leaves infected by Phytophthora colocasiae on wistar albinos rats. Biomed pharmacotherapy = Biomedecine pharmacotherapie. 2018;99:1009\u201313.","journal-title":"Biomed pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"4018_CR40","doi-asserted-by":"crossref","unstructured":"Eleazu K, Maduabuchi Aja P, Eleazu CO. Cocoyam (Colocasia esculenta) modulates some parameters of testosterone propionate-induced rat model of benign prostatic hyperplasia. Drug Chem Toxicol 2021:1\u201311.","DOI":"10.1080\/01480545.2021.1892956"},{"issue":"1","key":"4018_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0379-0738(91)90141-5","volume":"50","author":"LI Stowell","year":"1991","unstructured":"Stowell LI, Sharman LE, Hamel K. An enzyme-linked immunosorbent assay (ELISA) for prostate-specific antigen. Forensic Sci Int. 1991;50(1):125\u201338.","journal-title":"Forensic Sci Int"},{"key":"4018_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-1050-2_3","volume":"1180","author":"AT Feldman","year":"2014","unstructured":"Feldman AT, Wolfe D. Tissue processing and hematoxylin and eosin staining. Methods in molecular biology (Clifton NJ). 2014;1180:31\u201343.","journal-title":"Methods in molecular biology (Clifton NJ)"},{"issue":"1","key":"4018_CR43","first-page":"6","volume":"2","author":"E Omotoso Abayomi","year":"2014","unstructured":"Omotoso Abayomi E, Kenneth E, Mkparu K. Chemometric profiling of methanolic leaf extract of Cnidoscolus aconitifolius (Euphorbiaceae) using UV-VIS, FTIR and GC-MS techniques. J Med Plants Res. 2014;2(1):6\u201312.","journal-title":"J Med Plants Res"},{"issue":"12","key":"4018_CR44","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1080\/13880209.2016.1190383","volume":"54","author":"CO Eleazu","year":"2016","unstructured":"Eleazu CO. Characterization of the natural products in cocoyam (Colocasia esculenta) using GC\u2013MS. Pharm Biol. 2016;54(12):2880\u20135.","journal-title":"Pharm Biol"},{"key":"4018_CR45","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.biopha.2016.08.064","volume":"83","author":"W Kalu","year":"2016","unstructured":"Kalu W, Okafor P, Ijeh I, Eleazu C. Effect of kolaviron, a biflavanoid complex from Garcinia kola on some biochemical parameters in experimentally induced benign prostatic hyperplasic rats. Biomed Pharmacother. 2016;83:1436\u201343.","journal-title":"Biomed Pharmacother"},{"key":"4018_CR46","doi-asserted-by":"crossref","unstructured":"Eleazu CO, Iroaganachi M, Eleazu K. Ameliorative potentials of cocoyam (Colocasia esculenta L.) and unripe plantain (Musa paradisiaca L.) on the relative tissue weights of streptozotocin-induced diabetic rats. Journal of diabetes research 2013, 2013.","DOI":"10.1155\/2013\/160964"},{"key":"4018_CR47","unstructured":"Azubuike NC, Onwukwe OS, Onyemelukwe AO, Maduakor UC, Ifeorah IM, Okwuosa CN, Achukwu PU. Impact of Colocasia esculenta extract and fractions on high-fat diet-induced changes in body weight, adipose tissue and liver of rats. Pak J Pharm Sci 2018."},{"issue":"1","key":"4018_CR48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/j.1939-4640.1997.tb01876.x","volume":"18","author":"ROIJENJH Van","year":"1997","unstructured":"Van ROIJENJH, OOMS MP, WEBER RF, BRINKMANN AO, GROOTEGOED JA, VREEBURG JT. Comparison of the response of rat testis and accessory sex organs to treatment with testosterone and the synthetic androgen methyltrienolone (R1881). J Androl. 1997;18(1):51\u201361.","journal-title":"J Androl"},{"issue":"3","key":"4018_CR49","first-page":"271","volume":"2","author":"IL Princewill-Ogbonna","year":"2016","unstructured":"Princewill-Ogbonna IL, Ihedioha S, Ijeoma SN. Hematological and liver\/Kidney histology of rats feed with cocoyam (Colocasia esculenta L). Contemp J Empir Res. 2016;2(3):271\u201387.","journal-title":"Contemp J Empir Res"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-04018-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-023-04018-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-04018-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T20:31:46Z","timestamp":1702585906000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-023-04018-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4018"],"URL":"https:\/\/doi.org\/10.1186\/s12906-023-04018-4","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was done under the supervision and approval by the Office of Research, Innovation and Institutional Ethics Committee of Ebonyi state university, Nigeria (EBSU\/BCH\/ET\/21\/001). All procedures for animal studies were carried out and reported based on the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines and legislations consistent with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised in 1996) [] as well as National guidelines for the use of laboratory animals for research and teaching based on the principles of 3Rs, reduce refine or replace.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}